RFT1-CDG is a type of radio frequency technology used in the aviation industry. It is a system that allows aircraft to communicate with air traffic control and other aircraft in the vicinity. It is used to provide information on the aircraft's position, altitude, speed, and other data.

The symptoms of RFT1-CDG vary from person to person, but can include: developmental delays, intellectual disability, seizures, vision and hearing loss, skeletal abnormalities, and failure to thrive. Other symptoms may include: poor muscle tone, poor coordination, difficulty swallowing, and feeding problems.

RFT1-CDG is caused by mutations in the RFT1 gene. These mutations lead to a deficiency in the enzyme phosphomannomutase 2 (PMM2), which is responsible for the synthesis of mannose-6-phosphate, a sugar molecule that is essential for the proper sorting and transport of proteins in the body. This deficiency results in a wide range of symptoms, including intellectual disability, seizures, vision and hearing loss, skeletal abnormalities, and immunodeficiency.

Currently, there is no cure for RFT1-CDG. Treatment focuses on managing the symptoms and complications of the disorder. This may include physical therapy, occupational therapy, speech therapy, dietary modifications, and medications to manage seizures, gastrointestinal issues, and other symptoms. Genetic counseling is also recommended for individuals and families affected by RFT1-CDG.

The risk factors for RFT1-CDG include:

1. Family history of the disorder
2. Maternal consanguinity
3. Advanced maternal age
4. Unbalanced chromosomal rearrangements
5. Mutations in the RFT1 gene
6. Environmental factors such as exposure to certain toxins or medications.

At this time, there is no cure for RFT1-CDG. However, there are medications that can help manage the symptoms of the disorder. These medications include anticonvulsants, anti-inflammatory drugs, and vitamin supplements. Additionally, physical and occupational therapy can help improve motor skills and coordination.